Anxiety is more important than depression in MS -No Aaron P Turner and Kevin N Alschuler
Although anxiety is a concern in multiple sclerosis (MS), it is difficult to identify a mental health condition more pervasive and impactful in the lives of individuals with MS than depression. The annual prevalence of a Major Depressive Disorder is estimated to be nearly 16% and more than one-quarter of adults with MS will meet criteria at some point in their lifetime. 1 Perhaps even more notably, many studies have found that at any given time, roughly one-half of individuals with MS struggle with clinically meaningful levels of depressive symptoms. 1 In many cases, depression is intertwined with the characteristics of the disease process itself. Though inconsistent, research suggests depressive symptoms may be even more common during periods such as early in the disease process following diagnosis, during episodes of relapse and functional decline, and late in the disease with accumulating disability. 1 Individuals with depressive disorders may experience persistent low mood and/or loss of interest and pleasure in previously enjoyed activities, thoughts of guilt and worthlessness, as well as other physical symptoms such as disruption of sleep or appetite (too much or too little of either). Considering the variety of symptoms, it is not surprising that the effects of depression can be widespread:
Depression impacts quality of life
Life undoubtedly feels more difficult to a person experiencing depressed mood. It may be more difficult to engage in the world or may be harder to get joy from things that were previously enjoyable. With that in mind, it is unsurprising that individuals with MS who report higher levels of depression endorse a lower quality of life. 2 In fact, depression has often been found to be robustly and negatively correlated with quality of life even after adjusting for other relevant disease-related factors like physical disability. 2 
Depression impacts common MS symptoms
Numerous studies have considered the association between depressed mood and common symptoms of MS. Almost universally, these studies suggest bidirectional relationships, such that depressed mood and MS-related symptoms can cause each other to be worse. Fatigue, cognition, and pain represent three notable examples.
Fatigue is one of the most common symptoms of MS and one of the main contributors to activity limitations and participation restrictions. Being fatigued may limit an individual's ability to access meaningful and rewarding activity, which can facilitate depression. At the same time, depression itself can contribute to fatigue, and individuals with MS who are also depressed may experience a compounding of this already disabling phenomenon in a perniciously selfperpetuating downward spiral. 3 Similarly, cognitive dysfunction is estimated to impact roughly half of individuals with MS. Areas impacted often include information processing speed, attention and concentration, memory, and executive function. Like fatigue, symptoms of cognitive dysfunction can make it more difficult to effectively engage in world, which may contribute to low mood. However, it is also the case that many of the same cognitive difficulties seen in MS can also occur as the result of depression. Individuals with MS who are depressed demonstrate more cognitive dysfunction (objective and subjective) than those who are not (notably, the evidence is more consistent and robust for subjective dysfunction). 4, 5 The association between depression and cognitive performance in MS appears more pronounced as the complexity of the cognitive task increases. 4 Research also suggests that depression contributes to the experience and burden of pain. Pain is more common among individuals with MS who are depressed. 6 Not surprisingly, individuals who are depressed also experience more pain-related interference and utilize more healthcare resources for pain intervention as well.
Depression impacts utilization of social support
Depression may also have a detrimental impact on the personal and social relationships of individuals with Depression increases suicidal ideation and suicide Perhaps most concerning, depression places individuals with MS at higher risk of suicide. The preponderance of current evidence suggests that the risk of suicide in MS is between 1.6 and 2.3 times higher than the general population. 1 At any given time, as much as one-quarter of individuals with MS endorse some thoughts of self-harm. 1 Depression is associated with an increased risk of suicidal ideation, suicidal intent, and in combination with other mental disorders, suicide itself. [11] [12] [13] Management of individuals with MS is challenging, as there are so many facets of the disease. Depressed mood has the potential to impact almost all of themfrom quality of life to symptom severity to social engagement to self-care to patient safety. Routine screening, using brief measures like the Patient Health Questionnaire (PHQ)-2 or PHQ-9, is helpful in identifying symptoms that may not otherwise be discussed at clinical visits. 14 However, screening is ultimately only useful if accompanied by a plan for intervention. There is empirical support for a variety of pharmacologic and psychotherapeutic treatments for depression in MS. 15 Emerging research is also supporting new modalities of psychotherapy that can be delivered by telephone and/or videoconference, expanding the reach to patients who may not have previously been able to access such treatments. 1 All mental health conditions, including anxiety, are cause for concern and important to identify and treat. However, given the significance and breadth of its impact on people living with MS, depression should be a clinical priority.
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Anxiety is more important than depression in MS -Commentary Brigit A de Jong and Bernard MJ Uitdehaag
In this issue, the monthly Controversies series addresses the interesting topic of whether anxiety is more important than depression in multiple sclerosis (MS). The opponent teams, namely, Morrow 1 on one side and Turner and Alschuler 2 on the other side convincingly argue that both depression and anxiety have a huge impact on the lives of persons with multiple sclerosis (PwMS). However, the question whether one is more important than the other may be rather hard to answer with certainty. The issue can be approached in different ways, including a quantitative and a qualitative manner.
In the literature, consistent high prevalence rates of depression and anxiety among PwMS have been reported. A recent systematic literature review and meta-analysis reported prevalence rates of 31% (depression) and 22% (anxiety), respectively. 3 Due to the high degree of heterogeneity among the different studies, the prevalence rates varied considerably. This variation can partly be explained by different methodological approaches, for example, differences in sample sizes, recruitment resources, and diagnostic criteria which have been used, that is, based on self-report questionnaires or a disorder confirmed by a clinician. Therefore, it is uncertain if the reported difference in prevalence is significant and clinical relevant.
As clearly stated by Morrow, anxiety may be less recognized and has been less studied as compared to depression in MS. This may distort the comparison between depression and anxiety. Since anxiety seems to be often overlooked in MS, underreporting may result in missing the diagnosis and the opportunity to treat these symptoms with medication or psychotherapy. 4 Studies have shown that depression and anxiety are associated in MS, and they predict each other in both directions. 5 As reported by the opponent authors, anxiety and depression in MS are both associated with less adherence to medication and non-pharmacological therapies, increased risk of relapses, cognitive impairment, increased use of health care resources, mortality, fatigue, pain, as well as alcohol and other substance abuse. This all may contribute to less quality of life and less stable disease course of MS. Since both depression and anxiety are treatable, recognizing these conditions in PwMS is important.
To answer the question of whether anxiety or depression is more important in MS, we first need to better agree on the definitions for anxiety and depression to be used in MS. Besides this, robust prevalence rates of anxiety and depression in MS should be reliably determined in a population-based cohort of PwMS and the effects on outcomes measures should then be studied. Although MS is an incurable disease, there is an increasing number of disease-modifying treatments available. It is important to detect and treat anxiety and depression. Apart from its direct amelioration, this may also result in an increased treatment adherence and thus a more stable disease course and eventually a better quality of life for PwMS.
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